# Dapagliflozin to Prevent Anthracycline-Induced Cardiotoxicity

> **NCT06888505** · PHASE2 · COMPLETED · sponsor: **Hawler Medical University** · enrollment: 90 (actual)

## Conditions studied

- Anthracyclines-Induced Cardiotoxicity
- Cardiotoxicity

## Interventions

- **DRUG:** Dapagliflozin (Forxiga)
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06888505
- **Lead sponsor:** Hawler Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-09-01
- **Primary completion:** 2025-09-01
- **Final completion:** 2025-09-06
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2025-09-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06888505

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06888505, "Dapagliflozin to Prevent Anthracycline-Induced Cardiotoxicity". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT06888505. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*